INKT

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other life-threatening illnesses. The company's approach harnesses the unique properties of iNKT cells, which can recognize and kill tumor cells while modulating the immune system. MiNK's lead product candidate targets various solid tumors and hematologic malignancies. The company is advancing multiple programs through clinical development with the goal of creating off-the-shelf cell therapies that can be used across broad patient populations without the need for patient-specific manufacturing.